A randomised controlled trial comparing standard chemotherapy followed by resection versus Epirubicin, Cisplatin and Xeloda (ECX) chemotherapy followed by resection in patients with resectable adenocarcinoma of the oesophagus.

Trial Profile

A randomised controlled trial comparing standard chemotherapy followed by resection versus Epirubicin, Cisplatin and Xeloda (ECX) chemotherapy followed by resection in patients with resectable adenocarcinoma of the oesophagus.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2017 Results assessing efficacy, published in the Lancet Oncology.
    • 01 Jul 2015 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials record.
    • 23 Nov 2011 United Kingdom Clinical Research Network reports accrual to date changed from 105% to 106%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top